A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients. To determine the pharmacokinetic interactions of concurrent administration of ddI and ribavirin and correlate pharmacokinetic parameters with toxicity. To investigate antiviral activity of the combined regimen.

Patients receive ddI alone for 4 weeks, followed by 8 weeks of combination ddI/ribavirin. Patients who complete the first 12 weeks without major toxicity may receive an additional 12 weeks of combination therapy on an optional basis. Patients are followed for 60 days after the last treatment visit.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

Stable maintenance or prophylaxis therapy for opportunistic infection, if such therapy was administered for at least 30 days prior to study entry.

Isoniazid for chemoprophylaxis against Mycobacterium tuberculosis.

Fluconazole for mucosal candidiasis or cryptococcosis.

Acyclovir (up to 1.0 g/day).

Dapsone.

Ketoconazole.

Quinolones.

Tetracycline.

Vitamins and herbal therapies.

Antibiotics as clinically indicated.

Systemic corticosteroids for < 21 days for acute problems.

Regularly prescribed medications.

Patients must have:

HIV positivity by ELISA confirmed by Western blot.

CD4 count < 500 cells/mm3 within 30 days prior to study entry.

No active opportunistic infections requiring treatment (patients on stable maintenance and prophylaxis therapy for opportunistic infections for at least 30 days are permitted).

NOTE:

Enrollment of women is encouraged.

Prior Medication:

Allowed:

Prior stable maintenance or prophylaxis therapy for opportunistic infection, if administered for at least 30 days prior to study entry.

Exclusion Criteria

Concurrent Medication:

Excluded:

Concurrent rifampin or rifabutin.

Other anti-HIV drugs and investigational agents.

Biological response modifiers.

Ganciclovir or foscarnet.

Systemic cytotoxic chemotherapy.

Concurrent Treatment:

Excluded:

Concurrent radiation therapy other than limited localized therapy to the skin.